Fleury to Offer Veracyte Thyroid Cancer Expression Test in Brazil | GenomeWeb

NEW YORK (GenomeWeb) – Veracyte today said that it has signed a partnership with Fleury Medicine and Health to make its Afirma Gene Expression Classifier for thyroid cancer diagnosis available to patients in Brazil.

Fleury will exclusively offer the Afirma GEC through its diagnostics centers across Brazil. The genomic test will be offered when patients' thyroid nodule fine needle aspiration results are indeterminate following cytopathology review.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.